Guidelines

First recommendations for cancer screening in myositis issued


 

Consider doing this

Conditional recommendations (“clinicians should consider ...”) include the use of PET/CT for adults at high risk for cancer when an underlying cancer has not been detected at the time of IIM diagnosis. They also include a single screening test for anti-TIF1-gamma positive dermatomyositis patients whose disease onset was after age 40 and who have at least one additional risk factor.

Also conditionally recommended are upper and lower gastrointestinal endoscopy for patients at high risk when an underlying cancer is not found at the time of IIM diagnosis, nasoendoscopy in geographical regions with elevated risk for nasopharyngeal cancers, and screening for all IIM patients with red-flag symptoms or clinical features of cancer, including unexplained weight loss, family history of cancer, smoking, unexplained fever, or night sweats.

Guided steps

“I think clinicians have a lot of questions such as, ‘well, what should I do, when should I do it?’ These are important clinical questions, and we need guidance about this. We need to balance comprehensiveness with cost-effectiveness, and we need expert opinion about what steps we should take now and which should we take later,” Dr. Kolasinski said.

The guideline development process was supported by the University of Manchester, IMACS, National Institute for Health Research (United Kingdom), National Institutes of Health, National Health Service Northern Care Alliance, The Myositis Association, Myositis UK, University of Pittsburgh, Versus Arthritis, and the Center for Musculoskeletal Research. Dr. Oldroyd and Dr. Kolasinski reported having no relevant conflicts of interest.

Pages

Recommended Reading

Novel study offers clues to sex bias in lupus
MDedge Rheumatology
Litifilimab meets primary endpoint in phase 2 lupus trial
MDedge Rheumatology
Autoimmune diseases linked to spike in post-MI events
MDedge Rheumatology
Cell-killing cancer therapy treats lupus successfully
MDedge Rheumatology
Hormones’ impact described in transgender rheumatology patients
MDedge Rheumatology
Breakthrough COVID studies lend support to use of new boosters in immunosuppressed patients
MDedge Rheumatology
Evusheld PrEP may protect immunocompromised patients from severe COVID-19
MDedge Rheumatology
IVIG proves effective for dermatomyositis in phase 3 trial
MDedge Rheumatology
Metabolites may distinguish severe subtypes of PAH
MDedge Rheumatology
Rheumatic diseases and assisted reproductive technology: Things to consider
MDedge Rheumatology